Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive
Conditions
Brief summary
Opioid is recommended for moderate cancer pain in WHO 3-step analgesic ladder. Transdermal administration of the strong opioid fentanyl was originally developed for patients unable to swallow analgesics because of malignancies in the head and neck region or the gastrointestinal tract, painful lesions in the mouth, or periods of nausea, vomiting, or bowel obstruction. The EMA recognizes that in exceptional clinical circumstances, the 12 μg/h fentanyl patch could be considered. To our knowledge, there is not a phase III trial to explore the efficacy and safety of 12 μg/h fentanyl patch in opioid-naive patients with moderate cancer pain.
Interventions
DRUG2.5ug/h transdermal fentanyl
2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
DRUGOral immediate-released morphine
5mg immediate-released morphine every 4 hours, double dose before sleep.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18 years old or more; 2. ECOG PS ≤3 ; 3. Opioid tolerance not moderate pain patients (4≤ NRS ≤6 on 11 points, 0 no pain, 10 most pain); 4. No taking strong opioids for the last 30 days; 5. Estimated life expectancy of at least 3 months; 6. Ability to communicate effectively with the study personnel about the nature of their pain; 7. Ability to complete a diary; 8. Cancer pain is expected to be relatively stable and last for more than 48 hours; 9. The patient understands the research process, agrees to participate in the trial, cooperates with the treatment and visit plan, and signs an informed consent form.
Exclusion criteria
1. Known allergy to any ingredient in both fentanyl and morphine; 2. No cancer associated pain or the pain of unknown cause, such as osteoarthritis pain, acute abdominal pain; 3. Primary tumors or metastases in the brain; 4. An active skin disease that precluded application of the transdermal system; 5. Anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, etc.) is used during the study period, and the treatment has an impact on the analgesic effect or adverse reactions of analgesic drugs; 6. No bowel movement within 3 days before the screening period; 7. The patient has contraindications to the use of opioids: such as respiratory depression; head damage; paralytic intestinal obstruction; acute abdomen; chronic obstructive airway disease; pulmonary heart disease; chronic bronchial asthma; hypercapnia; 8. Used monoamine oxidase inhibitor within 1 week before randomization; 9. Any abnormal laboratory test results with obvious clinical significance, such as creatinine value ≥ 2 times the high limit of the normal value or ALT or AST ≥ 2.5 times the high limit of the normal value (for patients with liver metastases can be relaxed to ≥ 5 times the high limit of the normal value) ; 10. Patients with a history of drug abuse; 11. Patients with mental illness or cognitive impairment; 12. Pregnant or lactating women; subjects who have a pregnancy plan within 1 month after the test (including male subjects); 13. Participate in the drug trial (including the trial drug) within 3 months before the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the number of responder patients | 12 months | the number of responder patients is defined as patientswith a 20% reduction in pain intensity on the numerical rating scale. |
Outcome results
None listed